Subcutaneous implantable cardioverter defibrillator after transvenous lead extraction: safety, efficacy and outcome.
Implantable cardioverter defibrillator
S-ICD, Transvenous lead extraction
Subcutaneous implantable cardioverter defibrillator
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
13 Jul 2022
13 Jul 2022
Historique:
received:
20
03
2022
accepted:
29
06
2022
entrez:
13
7
2022
pubmed:
14
7
2022
medline:
14
7
2022
Statut:
aheadofprint
Résumé
Subcutaneous implantable cardioverter defibrillator (S-ICD) is a suitable alternative for transvenous ICD (TV-ICD) patients who have undergone transvenous lead extraction (TLE). Limited data are available on the outcome of S-ICD patients implanted after TLE. We assessed the safety, efficacy, and outcome of S-ICD implantation after TLE of TV-ICD. The study population consisted of 36 consecutive patients with a median age of 52 (44-66) years who underwent S-ICD implantation after TLE of TV-ICD. Indications for TLE were infection (63.9%) and lead malfunction (36.1%). During a median follow-up of 31 months, 3 patients (8.3%) experienced appropriate therapy and 7 patients (19.4%) experienced complications including inappropriate therapy (n = 4; 11.1%), isolated pocket erosion (n = 2; 5.5%), and ineffective therapy (n = 1; 2.8%). No lead/hardware dysfunction was reported. Premature device explantation occurred in 4 patients (11%). Eight patients (22.2%) died during follow-up, six of them (75%) because of refractory heart failure (HF). There were no S-ICD-related deaths. Predictors of mortality included NYHA class ≥ 2 (HR 5.05; 95% CI 1.00-26.38; p = 0.04), hypertension (HR 22.72; 95% CI 1.05-26.31; p = 0.02), diabetes (HR 10.64; 95% CI 2.05-55.60; p = 0.001) and ischemic heart disease (HR 5.92; 95% CI 1.17-30.30; p = 0.01). Our study provides evidences on the use of S-ICD as an alternative after TV-ICD explantation for both infection and lead failure. Mortality of S-ICD patients who underwent TV-ICD explantation does not appear to be correlated with the presence of a prior infection, S-ICD therapy (appropriate or inappropriate), or S-ICD complications but rather to worsening of HF or other comorbidities.
Sections du résumé
BACKGROUND
BACKGROUND
Subcutaneous implantable cardioverter defibrillator (S-ICD) is a suitable alternative for transvenous ICD (TV-ICD) patients who have undergone transvenous lead extraction (TLE). Limited data are available on the outcome of S-ICD patients implanted after TLE. We assessed the safety, efficacy, and outcome of S-ICD implantation after TLE of TV-ICD.
METHODS
METHODS
The study population consisted of 36 consecutive patients with a median age of 52 (44-66) years who underwent S-ICD implantation after TLE of TV-ICD.
RESULTS
RESULTS
Indications for TLE were infection (63.9%) and lead malfunction (36.1%). During a median follow-up of 31 months, 3 patients (8.3%) experienced appropriate therapy and 7 patients (19.4%) experienced complications including inappropriate therapy (n = 4; 11.1%), isolated pocket erosion (n = 2; 5.5%), and ineffective therapy (n = 1; 2.8%). No lead/hardware dysfunction was reported. Premature device explantation occurred in 4 patients (11%). Eight patients (22.2%) died during follow-up, six of them (75%) because of refractory heart failure (HF). There were no S-ICD-related deaths. Predictors of mortality included NYHA class ≥ 2 (HR 5.05; 95% CI 1.00-26.38; p = 0.04), hypertension (HR 22.72; 95% CI 1.05-26.31; p = 0.02), diabetes (HR 10.64; 95% CI 2.05-55.60; p = 0.001) and ischemic heart disease (HR 5.92; 95% CI 1.17-30.30; p = 0.01).
CONCLUSION
CONCLUSIONS
Our study provides evidences on the use of S-ICD as an alternative after TV-ICD explantation for both infection and lead failure. Mortality of S-ICD patients who underwent TV-ICD explantation does not appear to be correlated with the presence of a prior infection, S-ICD therapy (appropriate or inappropriate), or S-ICD complications but rather to worsening of HF or other comorbidities.
Identifiants
pubmed: 35831772
doi: 10.1007/s10840-022-01293-y
pii: 10.1007/s10840-022-01293-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022. The Author(s).
Références
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:2793–867.
doi: 10.1093/eurheartj/ehv316
Bongiorni MG, Kennergren C, Butter C, et al. The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction Outcomes. Eur Heart J. 2017;38:2995–3005.
doi: 10.1093/eurheartj/ehx080
Bongiorni MG, Burri H, Deharo JC, et al. 2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries. Europace. 2018;20:1217.
doi: 10.1093/europace/euy050
Boersma L, Barr C, Knops R, et al. EFFORTLESS Investigator Group. Implant and midterm outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: the EFFORTLESS Study. J Am Coll Cardiol. 2017;70:830–41.
doi: 10.1016/j.jacc.2017.06.040
Knops RE, OldeNordkamp LRA, Delnoy PHM, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med. 2020;383:526–36.
doi: 10.1056/NEJMoa1915932
Gold MR, Lambiase PD, El-Chami MF, et al. Primary results from the understanding outcomes with the S-ICD in primary prevention patients with low ejection fraction (UNTOUCHED) Trial. Circulation. 2021;143:7–17.
doi: 10.1161/CIRCULATIONAHA.120.048728
Rordorf R, Casula M, Pezza L, et al. Subcutaneous versus transvenous implantable defibrillator: an updated meta- analysis. Heart Rhythm. 2021;18:382–91.
doi: 10.1016/j.hrthm.2020.11.013
Quast ABE, van Dijk VF, Yap SC, Maass AH, Boersma LVA, Theuns DA, Knops RE. Six-year follow-up of the initial Dutch subcutaneous implantable cardioverter- defibrillator cohort: long-term complications, replacements, and battery longevity. J Cardiovasc Electrophysiol. 2018;29:1010–6.
doi: 10.1111/jce.13498
Migliore F, Pelliccia F, Autore C, et al. Subcutaneous implantable cardioverter defibrillator in cardiomyopathies and channelopathies. J Cardiovasc Med. 2018;19:633–42.
doi: 10.2459/JCM.0000000000000712
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e210–71.
pubmed: 29084733
Boersma L, Burke MC, Neuzil P, et al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. Heart Rhythm. 2016;13:157–64.
doi: 10.1016/j.hrthm.2015.08.039
Viani S, Migliore F, Tola G, et al. Use and outcomes of subcutaneous implantable cardioverter-defibrillator (ICD) after transvenous ICD extraction: an analysis of current clinical practice and a comparison with transvenous ICD reimplantation. Heart Rhythm. 2019;16:564–71.
doi: 10.1016/j.hrthm.2018.10.026
Chung DU, Tauber J, Kaiser L, et al. Performance and outcome of the subcutaneous implantable cardioverter-defibrillator after transvenous lead extraction. Pacing Clin Electrophysiol. 2021;44:247–57.
doi: 10.1111/pace.14157
Migliore F, Testolina M, Sagone A, et al. Multicenter experience with the evolution RL mechanical sheath for lead extraction using a stepwise approach: safety, effectiveness, and outcome. Pacing Clin Electrophysiol. 2019;42:989–97.
doi: 10.1111/pace.13700
Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14:e503–51.
doi: 10.1016/j.hrthm.2017.09.001
Migliore F, De Franceschi P, De Lazzari M, et al. Ultrasound-guided serratus anterior plane block for subcutaneous implantable cardioverter defibrillator implantation using the intermuscular two-incision technique. J Interv Card Electrophysiol. 2020;57:303–9.
doi: 10.1007/s10840-019-00669-x
Migliore F, Mattesi G, De Franceschi P, et al. Multicentre experience with the second-generation subcutaneous implantable cardioverter defibrillator and the intermuscular two-incision implantation technique. J Cardiovasc Electrophysiol. 2019;30:854–64.
doi: 10.1111/jce.13894
Migliore F, Viani S, Bongiorni MG, et al. Subcutaneous implantable cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy: results from an Italian multicenter registry. Int J Cardiol. 2019;280:74–9.
doi: 10.1016/j.ijcard.2019.01.041
Tjong FVY, Koop BE. The modular cardiac rhythm management system: the EMPOWER leadless pacemaker and the EMBLEM subcutaneous ICD. Herzschrittmacherther Elektrophysiol. 2018;29:355–61.
doi: 10.1007/s00399-018-0602-y
Black-Maier E, Lewis RK, Barnett AS, et al. Subcutaneous implantable cardioverter-defibrillator troubleshooting in patients with a left ventricular assist device: a case series and systematic review. Heart Rhythm. 2020;17:1536–44.
doi: 10.1016/j.hrthm.2020.04.019
RizwanSohail M, Henrikson CA, Jo Braid-Forbes M, et al. Increased long-term mortality in patients with cardiovascular implantable electronic device infections. Pacing Clin Electrophysiol. 2015;38:231–9.
doi: 10.1111/pace.12518